Beijing Bohui Innovation Biotechnology Group Co., Ltd. engages in the research and development, production, sale, and after-sale service of in-vitro diagnostic products in China and internationally. The company offers human immunoglobulin for rabies, tetanus, hepatitis B, and intravenous injections; human serum albumin; human prothrombin complex and human coagulation factor VIII; and vaccine for rabies. It also provides molecular diagnostics platform, such as Automatic Real-time Fluorescent Nucleic Acid Cartridge Analyzer(BHQ-III), and GenPlex BHF-VI Nucleic Acid Chip Analyzer; Trace Element Analyzers; Fluorescence Immunoassay Analyzers, and Quantum Dot Analyzer; and detection kits for respiratory, intestinal, reproductive infections, as well as trace element testing, allergen testing, and others. In addition, the company offers mass spectrometers, plate readers, and standardized ion sources; and flash, process, and preparative purification systems. The company was formerly known as Beijing Bohui Innovation Biotechnology Co., Ltd. and changed its name to Beijing Bohui Innovation Biotechnology Group Co., Ltd. in August 2021. Beijing Bohui Innovation Biotechnology Group Co., Ltd. was founded in 2001 and is headquartered in Beijing, China. Address: No. 9 Courtyard, Shengshengyuan Road, Beijing, China, 102206